Biosimilars
Highly similar follow-on biologic medicines supported by analytical, manufacturing, clinical, and regulatory comparability evidence.
Core metadata
- ID: biosimilars
- Era: Modern
- First known date: 2006 (exact)
- Region: European Union, United States, and global medicines regulation
- Review status: source_checked
- Maturity: established
Prerequisites
- Biopharmaceutical Manufacturing (biopharmaceutical_manufacturing)
- Monoclonal Antibodies (monoclonal_antibodies)
- Regulatory Drug Approval (regulatory_drug_approval)
Dependents
- None.
Fields
Field lanes
- Pharmaceuticals & Drug Development: Biologics & Vaccines
Node sources
- Review and Approval (U.S. Food and Drug Administration, 2026, official_agency) • Supports: node, maturity
Prerequisite edge evidence
Edge/source evidence summary:
- Prerequisite edges: 3
- Average edge confidence: 68%
- Prerequisite sources: 3
- expert_inference: 3
| Prerequisite | Type | Confidence | Evidence level | Note | Sources |
|---|---|---|---|---|---|
| Monoclonal Antibodies (monoclonal_antibodies) | enabling | 68% | expert_inference | Monoclonal Antibodies provides a capability that enables this technology without being the only possible path. |
|
| Biopharmaceutical Manufacturing (biopharmaceutical_manufacturing) | enabling | 68% | expert_inference | Biopharmaceutical Manufacturing provides a capability that enables this technology without being the only possible path. |
|
| Regulatory Drug Approval (regulatory_drug_approval) | enabling | 68% | expert_inference | Regulatory Drug Approval provides a capability that enables this technology without being the only possible path. |
|
This page is generated from canonical era JSON and is indexable by URL.